Exclusive Summary

• Backed by top-tier US-FDA and UK-MHRA GMP certifications with an existing US registration, enabling direct access to the highly regulated US market and fast-tracked global entry.
• Targets a massive and expanding market of over 55 million global dementia patients, strictly addressing the persistent demand for moderate-to-severe AD treatments in an aging world.
• Serves as a universally guideline-recommended, first-line standard of care for moderate-to-severe Alzheimer's disease, ensuring a long product life cycle and sustained clinical demand.
• Offers ready-to-launch Distribution partnerships with highly lucrative commercial profit margins and tender-winning pricing strategies driven by China's cost-efficient supply chain.